EPO published patent application EP3729459A1 for Glytec, LLC on March 25, 2026. The patent covers computer-implemented systems and methods for advising diabetes medications, specifically insulin dosing optimization. Key IPC classifications include G16H 50/20 (ICT for diagnosis), G16H 20/17 (ICT for pharmacotherapy), and A61M 5/172 (drug delivery systems). The patent is validated in 31 European designated states including major markets.

Patent publications do not create immediate compliance obligations for healthcare providers or pharmaceutical companies. However, competitors developing similar insulin dosing software or digital health tools should review this patent to assess potential infringement risks. The patent establishes intellectual property protection that may affect future product development in diabetes digital health technology across Europe.